Paragon Gene Therapy partners with clients that are at the forefront of next-generation therapeutics utilizing oncolytic viruses to improve current cancer therapies and practices.
Oncolytic viruses have tremendous therapeutic potential and will have a significant impact on public health. However, manufacturing constraints have become a bottle neck in the advancement of this technology. Our dedicated staff are uniquely skilled in solving these challenges and developing a scalable manufacturing process that can be the platform for commercial success. Leveraging our live-virus and VLP experiences as well as the latest manufacturing technologies (e.g. iCELLis fixed-bed bioreactors), Paragon expeditiously moves your oncolytic program forward for initial early-stage clinical evaluation while positioning for rapid progression to a late-stage and commercial setting.